Treatment of bone metastases from solid tumors with bone-modifying agents: a web survey of Italian oncologists investigating patterns of practice drug prescription and prevention of side effects
Supportive Care in Cancer · 2024
DOI: 10.1007/s00520-024-08392-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift Supportive Care in Cancer, 2024. Verfasst von Vittorio Fusco und 14 weiteren Autor:innen. Beteiligte Einrichtung: Oncology Unit, Department of Medicine, Azienda Ospedaliera-Universitaria "SS Antonio E Biagio e Cesare Arrigo", Alessandria, Italy. fusco.dott.vittor…. Hauptthemen laut MEDLINE: Bone Density Conservation Agents, Bone Neoplasms, Prostatic Neoplasms, Breast Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
Optimal use of bone-modifying agents (BMAs) in patients with bone metastases from solid tumors is uncertain in some aspects: the drug choice; the planned treatment duration and long-term therapy; the prevention and management of possible side effects, including renal toxicity, hypocalcaemia, and medication-related osteonecrosis of the jaw (MRONJ).
Methods
Italian oncologists were invited to fulfil a 24-question web survey about prescription of BMAs for bone metastases of breast cancer, prostate cancer, and other solid tumors. Prevention and management of side effects were also investigated.
Results
Answers of 191 oncologists were collected. BMAs are usually prescribed at the time of diagnosis of bone metastases by 87.0% (breast cancer) and 76.1% (solid tumors except breast and prostate cancers) of oncologists; the decision is more articulated for prostate cancer (endocrine-sensitive versus castration-resistant). The creatinine level (32.3%), the availability of patient venous access (15.8%), and the type of primary neoplasm (13.6%) are the most reported factors involved in choice between bisphosphonates and denosumab. Zoledronic acid every 3 months was considered as a valid alternative to monthly administration by 94% of Italian oncologists. Oncologists reported a good confidence with measures aimed to prevent MRONJ, whereas uncertainness about prevention and management of hypocalcemia was registered.
Conclusion
Italian oncologists showed a high attitude in prescribing bisphosphonates or denosumab at the time of diagnosis of bone metastases, with a large application of preventive measures of side effects. Further studies are needed to investigate some controversial aspects, such as optimal drug treatment duration and long-term drug schedules.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Oncology Unit, Department of Medicine, Azienda Ospedaliera-Universitaria "SS Antonio E Biagio e Cesare Arrigo", Alessandria, Italy. fusco.dott.vittorio@gmail.com.
- Translational Medicine Unit, DAIRI Department of Integration, Research and Innovation, Azienda Ospedaliera-Universitaria "SS Antonio E Biagio e Cesare Arrigo", Alessandria, Italy. fusco.dott.vittorio@gmail.com.
- Department of Oncology, University of Turin, Ordine Mauriziano Hospital, Turin, Italy.
- UOC Oncologia A, Policlinico Umberto 1, La Sapienza Università, Rome, Italy.
- Department of Medical Oncology, Cardinal Massaia Hospital, Asti, Italy.
- Department of Medical Oncology, IRCCS Istituto Romagnolo Per Lo Studio Dei Tumori (IRST) "Dino Amadori", Meldola, Italy.
Zitieren
APA
Fusco, V., Di Maio, M., Valsecchi, A. A., Santini, D., Tucci, M., De Giorgi, U., Bossi, P., Ibrahim, T., Cavanna, L., Lanzetta, G., Rossi, M., Rossetti, G., Airoldi, M., Comandone, A., & Cinieri, S. (2024). Treatment of bone metastases from solid tumors with bone-modifying agents: a web survey of Italian oncologists investigating patterns of practice drug prescription and prevention of side effects. Supportive Care in Cancer. https://doi.org/10.1007/s00520-024-08392-8
Vancouver
Fusco V, Di Maio M, Valsecchi AA, Santini D, Tucci M, De Giorgi U, et al. Treatment of bone metastases from solid tumors with bone-modifying agents: a web survey of Italian oncologists investigating patterns of practice drug prescription and prevention of side effects. Supportive Care in Cancer. 2024. doi:10.1007/s00520-024-08392-8
BibTeX
@article{Fusco2024,
author = {Fusco, Vittorio and Di Maio, Massimo and Valsecchi, Anna Amela and Santini, Daniele and Tucci, Marcello and De Giorgi, Ugo and Bossi, Paolo and Ibrahim, Toni and Cavanna, Luigi and Lanzetta, Gaetano and Rossi, Maura and Rossetti, Giorgia and Airoldi, Mario and Comandone, Alessandro and Cinieri, Saverio},
title = {Treatment of bone metastases from solid tumors with bone-modifying agents: a web survey of Italian oncologists investigating patterns of practice drug prescription and prevention of side effects},
journal = {Supportive Care in Cancer},
year = {2024},
doi = {10.1007/s00520-024-08392-8}
}
EUVIMED